1.33
-0.01
(-0.75%)
May 23 - Close
NYSEMKT
real-time data -
Disclaimer
Currency in USD
| Range | 1.23 - 1.33 |
| 52 week | 0.90 - 1.76 |
| Open | 1.32 |
| Vol / Avg. | 330,164.00/109,305.00 |
| Mkt cap | 49.65M |
| P/E | - |
| Div/yield | - |
| EPS | -0.26 |
| Shares | 37.33M |
| Beta | 0.89 |
| Inst. own | 8% |
Events
Mar 19, 2013
NOVABAY PHARMACEUTICALS INC at Roth Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -6363.49% | -101.15% |
| Operating margin | -5534.92% | -119.61% |
| EBITD margin | - | -114.70% |
| Return on average assets | -92.81% | -39.93% |
| Return on average equity | -131.88% | -60.08% |
| Employees | 26 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 550, 5980 Horton Street
EMERYVILLE, CA 94608
United States - Map
+1-510-8998800 (Phone)
+1-510-2250371 (Fax)
EMERYVILLE, CA 94608
United States - Map
+1-510-8998800 (Phone)
+1-510-2250371 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
NovaBay Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. The Company�s Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The Company is focused in three therapeutic markets, which includes Dermatology, Ophthalmology and Urology. The Company is also developing another class of molecule, NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care.
Officers and directors
| Ramin Najafi Ph.D. | Chairman of the Board, President, Chief Executive Officer | |
| Thomas J. Paulson | Chief Financial Officer, Treasurer, Secretary | |
| Keith R. Bley Ph.D. | Senior Vice President - Product Development | |
| David W. Stroman Ph.D. | Senior Vice President - Ophthalmic Product Development | |
| Roy J. Wu | Senior Vice President - Business & Corporate Development | |
| T. Alexander McPherson M.D., Ph.D. | Lead Independent Director | |
| Charles J. Cashion | Independent Director | |
| Anthony Dailley DDS | Independent Director | |
| Paul E. Freiman | Independent Director | |
| Gail J. Maderis | Independent Director |